Cytotoxic T lymphocytes generated by short-term in vitro TCR stimulation in the presence of IL-4 are therapeutically effective against B16 melanoma

Journal of Biomedical Science

Volumn 10, Issue 6, 2003, Pages 644-650

  Chang, Mei Ling ^b   Chen, Yi Ting ^b   Su, Yu Chia ^b   Kung, John T ^a  

^a INSTITUTE OF MOLECULAR BIOLOGY   (Taiwan)

^b NONE

Author keywords

Adoptive transfer; CTL; IL 4; Immunotherapy; Melanoma; P14 TCR

Indexed keywords

CD8 ANTIGEN; GLYCOPROTEIN; INTERLEUKIN 2; INTERLEUKIN 4; ISOPROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; ANTIGEN; PROTEIN P14;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CELL STRAIN; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY; IMMUNE RESPONSE; IN VITRO STUDY; INOCULATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR GROWTH; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; CELL CULTURE; CYTOTOXIC T LYMPHOCYTE; EXPERIMENTAL MELANOMA; IMMUNOLOGY; LUNG; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE; CANCER THERAPY; CELL LINE; CELL STIMULATION; CELL SURVIVAL; COLONY FORMING CELL; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG SCREENING; FEMALE; MALE; MELANOMA CELL; REDUCTION;

ANIMALS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; INTERLEUKIN-4; LUNG; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; RECEPTORS, ANTIGEN, T-CELL; SURVIVAL RATE; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0242268022     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1159/000073530     Document Type: Article

References (30)

1. Chang J, Thomas C 3d, Kung J. Mitogen-induced IL-2 production and proliferation at defined stages of T helper cell development. J Immunol 147:860-866;1991.
2. Dialynas D, Quan Z, Wall K, Pierres A, Quintans J, Loken M, Pierres M, Fitch F. Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule. J Immunol 131:2445-2451;1983.
3. Dobrzanski MJ, Reome JB, Dutton RW. Therapeutic effects of tumor-reactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases. J Immunol 162:6671-6680;1999.
4. Gilboa E. How tumors escape immune destruction and what we can do about it. Cancer Immunol Immunother 48:382-385;1999.
5. Gillis S, Ferm M, Ou W, Smith K. T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol 120:2027-2032;1978.
6. Golumbek PT, Lazenby AJ, Levitsky HI, Jaffee LM, Karasuyama H, Baker M, Pardoll DM. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254:713-716;1991.
7. Gouttefangeas C, Rammensee H-G. Problem solving for tumor immunotherapy. Natnol Biotech 18:491;2000.
8. Greenberg PD. Adoptive T cells therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 49:281;1991.
9. Gregoire C, Rebai N, Schweisguth F, Necker A, Mazza G, Auphan N, Millward A, Schmitt-Verhulst A, Malissen B. Engineered Secreted T-Cell receptor αβ heterodimers. Proc Natl Acad Sci USA 88:8077-8081;1991.
10. Holly L, Hanson DLD, Ikeda H, White JM, Shankaran V, Old LJ, Shiku H, Schreiber RD, Allen PM. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity 13:265-276;2000.
11. Huang L-R, Chen F-L, Chen Y-T, Lin Y-M, Kung JT. Potent induction of long-term CD8+ T cell memory by short-term IL-4 exposure during T cell receptor stimulation. Proc Natl Acad Sci USA 97:3406-3411;2000.
12. Kyburz D, Aichele P, Speiser DE, Hengartner H, Zinkernagel R, Pircher H. T cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptide. Eur J Immunol 23:1956;1993.
13. Ledbetter JA, Herzenberg LA. Xenogeneic monoclonal antibodies to mouse lymphoid differentiation antigens. Immnunol Rev 47:63-90;1979.
14. Moskophidis D, Lechner F, Pircher H, Zinkernagel RM. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 362:758-761;1993.
15. Ohara J, Ep W. Production of a monoclonal antibody to and molecular characterization of B-cell stimulatory factor-1. Nature 315:333;1985.
16. Pircher H, Michalopoulos EE, Iwamoto A, Ohashi PS, Baenziger J, Hengartner H, Zinkernagel RM, Mak TW. Molecular analysis of the antigen receptor of virus-specific cytotoxic T cells and identification of a new Vα family. Eur J Immunol 17:1843-1846;1987.
17. a encoded antigens in T cell receptor V beta 8.1 chain transgenic mice. EMBO J 8:719-727;1989.
18. Pircher H, Burki K, Lang R, Hengartner H, Zinkernagel RM. Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature 342:559;1989.
19. Prevost-Blondel A, Zimmermann C, Stemmer C, Kulmburg P, Rosenthal FM, Pircher H. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J Immunol 161:2187-2194;1998.
20. Prevost-Blondel AMN, Rawiel M, Pircher H. Differential requirement of perforin and IFN-γ in CD8 T cell-mediated immune responses against B16. F10 melanoma cells expressing a viral antigen. Eur J Immunol 30:2507-2515;2000.
21. Rosenberg S, Lotze M, Muul L, Leitman S, Chang A, Ettinghausen S, Matory Y, Skibber J, Shiloni E, Vetto J, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485-1492;1985.
22. Rosenberg S, Yang J, Topolian SL, Schwartzentruber D, Weber J, Parkinson D, Seipp C, Einhorn J, White D. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA271:907-913;1994.
23. Rosenberg S, Yang J, White D, Steinberg S. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigen mediating response. Ann Surg 228:307-319;1998.
24. Shankaran V, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410:1107-1111;2001.
25. Sobek V, Balkow S, Korner H, Simon MM. Antigen-induced cell death of T effector cells in vitro proceeds via the Fas pathway, requires endogenous interferon-gamma and is independent of perforin and granzymes. Eur J Immunol 32:2490-2499;2002.
26. Staerz U, Rammensee H, Benedetto J, Bevan M. Characterization of a murine monoclonal antibody specific for an allotypic determinant on T cell antigen receptor. J Immunol 134:3994-4000;1985.
27. Sugawa S, Palliser D, Eisen HN, Chen J. How do cultured CD8+ murine T cell clones survive repeated ligation of the TCR? Int Immunol 14:23-30;2002.
28. Unkeless JC. Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. J Exp Med 150:580-596;1979.
29. Wakatsuki Y, Neurath M, Max E, Strober W. The B cell-specific transcription factor BSAP regulates B cell proliferation. J Exp Med 179:1099-1108;1994.
30. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 99:16168-16173;2002.